000 05303nam a22006615i 4500
001 978-3-319-66833-8
003 DE-He213
005 20210420091652.0
007 cr nn 008mamaa
008 180510s2018 gw | s |||| 0|eng d
020 _a9783319668338
_9978-3-319-66833-8
024 7 _a10.1007/978-3-319-66833-8
_2doi
050 4 _aHD28-70
072 7 _aKJMV6
_2bicssc
072 7 _aBUS087000
_2bisacsh
072 7 _aKJMV6
_2thema
072 7 _aPDG
_2thema
082 0 4 _a658.514
100 1 _aGassmann, Oliver.
_eauthor.
_4aut
_4http://id.loc.gov/vocabulary/relators/aut
245 1 0 _aLeading Pharmaceutical Innovation
_h[electronic resource] :
_bHow to Win the Life Science Race /
_cby Oliver Gassmann, Alexander Schuhmacher, Max von Zedtwitz, Gerrit Reepmeyer.
250 _a3rd ed. 2018.
264 1 _aCham :
_bSpringer International Publishing :
_bImprint: Springer,
_c2018.
300 _aXV, 179 p. 41 illus., 3 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
505 0 _aInnovation: Key to Success in the Pharmaceutical Industry -- The Industry Challenge: Who Would Want to Be in This Business?- The Science and Technology Challenge: How to Find New Drugs -- The Pipeline Challenge: How to Organize Innovation -- The Make-or-Buy Challenge: How to In- and Outsource Innovation -- The Open Innovation Challenge: How to Partner for Innovation -- The Internationalization Challenge: Where to Access Innovation -- Future Directions and Trends.
520 _aThis book investigates and highlights the most critical challenges the pharmaceutical industry faces in an increasingly competitive environment of inflationary R&D investments and tightening cost control pressures. The authors present three sources of pharmaceutical innovation: new management methods in the drug development pipeline; new technologies as enablers for cutting-edge R&D; and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. New models and methods are illustrated with cases from Europe, the US, and Asia. This third fully revised edition was expanded to reflect the latest updates in open and collaborative innovation, the greater strategic importance of venture capital and early-stage investments, and the new range of emerging technologies now being put to use in pharmaceutical innovation. Health care innovation is possibly the greatest opportunity and challenge of our generation. This important book shows how pharmaceutical companies will continue to play an instrument role in making our lives better. Stefan Thomke, William Barclay Harding Professor of Business Administration, Harvard Business School Very comprehensive review and analysis of current challenges for the biopharmaceutical industry. To stay competitive in this new technology driven environment, the industry started to develop new partnership models to close the innovation gap and provide patients with the relevant healthcare toolkits at the convergence of pharmaceuticals, diagnostics and IT technologies. Very exciting times ahead well depicted in this book! Karima Boubekeur, VP Emerging Portfolio and Search & Evaluation, AstraZeneca Great. The 3rd edition is not only an update. It's an outstandingly featured summary on the challenges of pharma innovation. Eckard von Keutz, SVP and Head of Early Development, Bayer Healthcare.
650 0 _aManagement.
650 0 _aIndustrial management.
650 0 _aPharmaceutical technology.
650 0 _aPharmacy management.
650 0 _aPharmacy.
650 0 _aHealth care management.
650 0 _aHealth services administration.
650 0 _aHealth economics.
650 1 4 _aInnovation/Technology Management.
_0https://scigraph.springernature.com/ontologies/product-market-codes/518000
650 2 4 _aPharmaceutical Sciences/Technology.
_0https://scigraph.springernature.com/ontologies/product-market-codes/B21010
650 2 4 _aPharmacoeconomics and Health Outcomes.
_0https://scigraph.springernature.com/ontologies/product-market-codes/H69020
650 2 4 _aPharmacy.
_0https://scigraph.springernature.com/ontologies/product-market-codes/F00008
650 2 4 _aHealth Care Management.
_0https://scigraph.springernature.com/ontologies/product-market-codes/527030
650 2 4 _aHealth Economics.
_0https://scigraph.springernature.com/ontologies/product-market-codes/W35000
700 1 _aSchuhmacher, Alexander.
_eauthor.
_4aut
_4http://id.loc.gov/vocabulary/relators/aut
700 1 _avon Zedtwitz, Max.
_eauthor.
_4aut
_4http://id.loc.gov/vocabulary/relators/aut
700 1 _aReepmeyer, Gerrit.
_eauthor.
_4aut
_4http://id.loc.gov/vocabulary/relators/aut
710 2 _aSpringerLink (Online service)
773 0 _tSpringer Nature eBook
776 0 8 _iPrinted edition:
_z9783319668321
776 0 8 _iPrinted edition:
_z9783319668345
776 0 8 _iPrinted edition:
_z9783030097820
856 4 0 _uhttps://s443-doi-org.br.lsproxy.net/10.1007/978-3-319-66833-8
912 _aZDB-2-BUM
912 _aZDB-2-SXBM
942 _2ddc
_cEBK
999 _c374011
_d332573